BackPliant Therapeutics Overview
Pliant Therapeutics Inc

Pliant Therapeutics P/E Ratio

Latest P/E ratio for Pliant Therapeutics: -0.74 — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

P/E Ratio

-0.74

P/E Ratio

-0.74

The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.

P/E Ratio (Comparison Companies)

Loading

P/E Ratio History

Loading

P/E Ratio Comparison

Loading

Pliant Therapeutics (PLRX) FAQ

Pliant Therapeutics (PLRX) currently reports a P/E ratio of -0.74. That is below the Healthcare sector average of 25.3. Use the charts on this page to explore Pliant Therapeutics's P/E ratio history and peer comparisons.

Pliant Therapeutics's P/E ratio of -0.74 is lower than the Healthcare sector average of 25.3. That is roughly 102.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Pliant Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -0.74, PLRX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -0.74, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.3. From there, open related valuation or income-statement pages for Pliant Therapeutics, and consider following PLRX for alerts when major investors trade the stock.

Pliant Therapeutics is classified in the Healthcare sector. On P/E ratio, it currently shows -0.74 versus a sector average near 25.3. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PLRX with unrelated industries.